-
Mashup Score: 2
Among adults with pulmonary arterial hypertension, patient characteristics, mortality and treatment varied across four U.S. census regions, according to results published in Annals of the American Thoracic Society.“We found differences between regions, which was not at all unexpected,” Peter J. Leary, MD, PhD, director of the pulmonary vascular disease program at the University of
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 2
Among adults with pulmonary arterial hypertension, patient characteristics, mortality and treatment varied across four U.S. census regions, according to results published in Annals of the American Thoracic Society.“We found differences between regions, which was not at all unexpected,” Peter J. Leary, MD, PhD, director of the pulmonary vascular disease program at the University of
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 35
Biologic should arrive on pharmacy shelves before May
Source: www.medpagetoday.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3Benefit of upfront combination therapy not seen in low-risk PAH - 1 month(s) ago
Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.“For the time being, we need to follow the current European guidelines and begin with a dual combination therapy from the outset for all patients diagnosed with PAH,”
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 3Benefit of upfront combination therapy not seen in low-risk PAH - 1 month(s) ago
Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.“For the time being, we need to follow the current European guidelines and begin with a dual combination therapy from the outset for all patients diagnosed with PAH,”
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 3
Selexipag is an oral prostacyclin receptor agonist, indicated for pulmonary arterial hypertension to delay disease progression and reduce the risk of pulmonary arterial hypertension–related hospitalization. SelexiPag: tHe usErs dRug rEgistry (NCT03278002) was a US-based, prospective, real-world registry of selexipag-treated patients.
Source: www.jhltonline.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 7Central role of ubiquitin-specific protease 8 in leptin signaling pathway in pulmonary arterial hypertension - 3 month(s) ago
Leptin receptor (ObR-b) is overexpressed in pulmonary artery smooth muscle cells (PA-SMCs) from patients with pulmonary arterial hypertension (PAH) and is implicated in both mechanisms that contribute to pulmonary vascular remodeling: hyperproliferation and inflammation. Our aim was to investigate the role of ubiquitin-specific peptidase 8 (USP8) in ObR-b overexpression in PAH.
Source: www.jhltonline.orgCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 58Reversing a disease: FOXF1 fixes Pulmonary Arterial Hypertension - 4 month(s) ago
Pulmonary arterial hypertension (PAH) is a debilitating disease that worsens over time; ultimately leading to right heart failure and death. PAH is caused by dysfunction of cells in our lung arteries called endothelial cells. Previous studies have shown that lung endothelial cell dysfunction in PAH is related to DNA damage not being repaired. In a recent study led by Sarasa Isobe, MD, PhD, and BASE Director Marlene Rabinovitch, MD and published in Nature Communications, investigators identified the
Source: med.stanford.eduCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Addressing SDoH and Decreasing Disparities in PAH: A Focus on Technology, Tools & Advancing Therapies - 6 month(s) ago
Through the lens of SDoH, this program will explore the burdens many PAH patients face including access to care and prejudices real or perceived.
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Patient-Centered Management of Pulmonary Arterial Hypertension With Prostacyclin Therapy - 6 month(s) ago
Are you up to speed on optimal medical treatment for pulmonary arterial hypertension (PAH)? Our experts discuss a couple of cases to highlight when best to use certain medications.
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
Published in @AnnalsATS: Among adults with pulmonary arterial hypertension (#PAH)❤️, patient characteristics, mortality and treatment varied across four U.S. census regions. @CardiologyToday Read more🔽 https://t.co/MQi4MANKAU